Vimta Labs Executive and Leadership Team

Harita Vasireddi, the Chief Executive Officer at Vimta Labs, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the integration of scientific and regulatory services, the Chief Executive Officer ensures alignment with the complex needs of global bio/pharmaceutical partners. This leadership role involves driving expansion across international markets while maintaining the highest standards of quality control and laboratory excellence. By fostering innovation in drug development support, Harita Vasireddi directly impacts the operational success of the company. The Chief Executive Officer manages high-level stakeholder relationships and guides the executive team toward achieving sustainable growth. Through consistent focus on technical precision and regulatory compliance, the Chief Executive Officer secures the market position of the firm as a premier contract research organization. Ultimately, Vasireddi maintains the integrity of all scientific processes across the entire enterprise.

Siva Krishna Kambhampati, the Chief Financial Officer at Vimta Labs, manages the fiscal health and capital allocation strategies for the organization. Overseeing financial planning, reporting, and risk management, the Chief Financial Officer ensures the company maintains the necessary resources to support advanced preclinical and clinical research infrastructure. This leadership role involves optimizing budgetary efficiency across all cGMP laboratory services, including microbiology and stability testing. By analyzing market trends and operational costs, Siva Krishna Kambhampati directly influences the strategic investment decisions required for technological upgrades. The Chief Financial Officer collaborates with the executive board to ensure financial transparency and long-term stability. Through rigorous oversight of fiscal performance, the Chief Financial Officer supports the expansion of service portfolios in the competitive pharmaceutical landscape. Ultimately, Kambhampati drives the financial discipline required to sustain the company's commitment to scientific excellence.

Rajesh Medisetty, the President, Biologics & Analytical at Vimta Labs, directs the specialized laboratory operations focused on method development, extractables, and leachables. Overseeing the technical execution of complex analytical testing, the President, Biologics & Analytical ensures that all processes meet stringent cGMP requirements for pharmaceutical clients. This leadership role involves managing the physical characterization and quality control departments to guarantee data accuracy and regulatory compliance. By implementing advanced analytical methodologies, Rajesh Medisetty directly enhances the service capabilities of the firm within the global biologics market. The President, Biologics & Analytical coordinates with cross-functional teams to streamline process validation and ensure rapid turnaround for critical drug development projects. Through continuous improvement of laboratory workflows, the President, Biologics & Analytical maintains the high standards expected by international regulatory bodies. Ultimately, Medisetty ensures the delivery of precise scientific insights for every client engagement.

Upendra Bhatnagar, the President, Preclinical Business at Vimta Labs, directs the strategic initiatives and operational execution of the preclinical research division. Overseeing the design and implementation of comprehensive drug development studies, the President, Preclinical Business ensures that all research activities adhere to global regulatory standards. This leadership role involves managing the scientific teams responsible for evaluating drug safety and efficacy before clinical trials commence. By optimizing research protocols and laboratory resources, Upendra Bhatnagar directly supports the accelerated development timelines required by pharmaceutical partners. The President, Preclinical Business collaborates with internal stakeholders to integrate preclinical findings into broader regulatory submissions. Through the application of rigorous scientific methodology, the President, Preclinical Business drives the growth of the research portfolio across diverse therapeutic areas. Ultimately, Bhatnagar ensures the delivery of high-quality, reliable data that forms the foundation for successful pharmaceutical innovation.